Yi long Wu
Lifetime Director of Guangzhou Provincial People's Hospital
Caicun Zhou
Director of Oncology Department, Shanghai Pulmonary Hospital
Li Zhang
Director of Internal Medicine, Sun Yat-sen University Cancer Center
Shun Lu
Director of Oncology Department ，Shanghai Lung Tumor Clinical Medical Center
Alex A. Adjei
Director of Oncology Department，Mayo Clinic
Yi long Wu
Academician of the American College of SurgeryAcademician of the American College of Surgery, Lifetime Director of Guangzhou Provincial People's Hospital
Prof. Wu is the awardee of “IASLC Scientific Award” and “Wu-Yang Award”; recipient of the special allowance of the State Council; “Outstanding Mid-Aged Expert of the National Health and Family Planning Commission”; “National Outstanding Professional and Technical Personnel”; “100 outstanding talents in Guangdong Province”; Highly Cited Researched in the field of clinical medicine 2018-2019..
Prof. Wu leads Chinese clinical research on lung cancer to keep pace with the international level and makes great contributions to establishing the precision treatment principle in EGFR-mutated lung cancer globally. His research outcomes have been adopted and translated into international treatment guidelines for lung cancer.
Prof. Wu have received the second prize of “National Science&Technology Progress Award” (once); the first prize of “Chinese Medical Science and Technology Award” (once); the first prize (twice) and second prize (four times) of awards at provincial level, all of which rank the first place. He has supervised over 80 students to obtain master of medicine, PhD degree and conduct post-doctoral work. He has directed more than 20 national and provincial research projects including “National Key Industry Program” and “National Natural Science Foundation of China”. He has also directed 8 global clinical trials.
Caicun Zhou
Director of Oncology Department, Shanghai Pulmonary Hospital
Prof. Zhou focuses on research of the molecular biology of lung cancer and individualized treatment of cancer. Received Research funds from Chinse government including national 863 project from the minister of Science and Technology, National Natural Science Foundation of China, key project funds from the Science and Technology Commission of Shanghai Municipality. He has published more than 200 articles in domestic and foreign journals, including more than 100 SCI papers including Lancet Oncology, JCO, Annals of Oncology, JTO and Cancer. Took part in or initiated more than 30 clinical trials in the field of lung cancer.
Li Zhang
Director of Internal Medicine, Sun Yat-sen University Cancer Center
Prof. Zhang is good at chemotherapy, targeted therapy, immunotherapy and multidisciplinary comprehensive therapy for primary lung cancer and nasopharyngeal cancer. He also has rich experience in the procedures, principles, organization and implementation of clinical research on new anti-cancer drugs, and has presided over a number of international multi-center clinical studies and national multi-center clinical studies. In recent years, he has been published in internationally renowned oncology journals such as The Lancet, The Lancet Oncology, Clinical Oncology, JAMA Oncology, Yearbook of Oncology, JNCI, JTO and other journals. Published more than 100 high-level papers. The research results have been given oral presentations at the American Society of Clinical Oncology Annual Meeting, the European Medical Oncology Annual Meeting and the World Conference on Lung Cancer for many times. He has won the second prize of the National Science and Technology Progress Award, the first prize of the Guangdong Provincial Science and Technology Research Achievement Award, and the third prize of the Guangdong Medical and Health Science and Technology Progress Award.
Shun Lu
Director of oncology department ，Shanghai Lung Tumor Clinical Medical Center
Lu Shun, director of Oncology Department (Shanghai Lung Tumor Clinical Medical Center), is MD, PhD and doctoral supervisor. More than 200 peer reviewed papers were published in several journals, such as Journal of Clinical Oncology，PNAS, Clinical Cancer Research, Chest, Journal of Thoracic Oncology, Nature Communication and etc. The total IF is 338.8.
Lu received several Chinese National Grant and Funding, including National Science and Technology major project, national program on Key Basic Research Project of China in 2016, National Natural Science Foundation of China in 2016, Chinese National Science and Technology Promotion Co-operation project in 2012, National High-tech R&D Program of China (863 Program) in 2012 and 2008, Chinese National Science and Technology Promotion project in 2007 and etc. He studies novel targeted agents, immunotherapy drug, and has expertise in lung and other thoracic tumor. He also severs as the P.I or CO-P.I of many international clinical trials.
Alex A. Adjei
Director of Oncology Department，Mayo Clinic
Alex A. Adjei, M.D., Ph.D., is a medical oncologist at Mayo Clinic whose research includes drug development, regulatory science and early-phase clinical trials. Dr. Adjei works to bring promising new compounds from the laboratory to initial human testing and to ultimately gain regulatory approval for their use in patients. Dr Adjei's research also focuses on health disparities, global oncology, new drug treatments for lung cancer, and understanding how different patients are affected by drug toxicities.
Lin Shen
Vice President of Peking University Cancer Hospital
The professional direction of Prof Shen is the diagnosis and treatment of digestive system tumors, especially the comprehensive treatment and individualized treatment of gastrointestinal tumors. She enjoys a high reputation in the field of digestive system tumors in China. She has extensive experience in preoperative staging, treatment decision-making, and postoperative treatment of gastrointestinal tumors. She also has extensive experience in esophageal cancer, gastrointestinal stromal tumor, neuroendocrine tumor, and pancreatic cancer.
Jin Li
Director of Oncology Department ，Shanghai Oriental Hospital
In the past ten years, more than 100 clinical studies have been carried out, including 18 international and domestic multi-center clinical studies, and more than 30 international multi-center clinical studies. Most prominently, he led the Chinese clinical oncology team to complete the world's first phase I-III clinical study of a small molecule targeted drug for the treatment of gastric cancer (which has been approved by the CFDA as a new drug), and represented the Chinese team to attend the ASCO conference and do Conference keynote speech. This research was rated as the first ASCO excellent paper selected by Chinese scholars in the world in 50 years.
Li Zhang
Director of Internal Medicine, Sun Yat-sen University Cancer Center
Prof. Zhang is good at chemotherapy, targeted therapy, immunotherapy and multidisciplinary comprehensive therapy for primary lung cancer and nasopharyngeal cancer. He also has rich experience in the procedures, principles, organization and implementation of clinical research on new anti-cancer drugs, and has presided over a number of international multi-center clinical studies and national multi-center clinical studies. In recent years, he has been published in internationally renowned oncology journals such as The Lancet, The Lancet Oncology, Clinical Oncology, JAMA Oncology, Yearbook of Oncology, JNCI, JTO and other journals. Published more than 100 high-level papers. The research results have been given oral presentations at the American Society of Clinical Oncology Annual Meeting, the European Medical Oncology Annual Meeting and the World Conference on Lung Cancer for many times. He has won the second prize of the National Science and Technology Progress Award, the first prize of the Guangdong Provincial Science and Technology Research Achievement Award, and the third prize of the Guangdong Medical and Health Science and Technology Progress Award.
Hetty Caraway
professor,Cleverland Clinic
Dr. Hetty Caraway is a staff associate professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic.
Dr. Carraway is American Board of Internal Medicine certified in medical oncology and internal medicine. She is a member of numerous professional organizations including the American Society of Hematology (ASH), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Eastern Cooperative Oncology Group (ECOG), SWOG, and the American College of Physicians. She has co-authored numerous peer-reviewed publications, review articles, editorials, abstracts and book chapters. She is nationally sought for her expertise in hematologic malignancies (AML, ALL and MDS). As a translational clinical scientist, Dr. Carraway’s research is focused on experimental therapeutics of acute leukemias and myeloproliferative diseases.
Xiaohua Wu
Director of Department of Gynecology, Fudan University Affiliated Cancer Hospital
Prof. Xiaohua Wu got his Bachelor of Medicine from Bengbu Medical College, Anhui Province, in 1987 and M.D. of Oncology at Shanghai Medical University in 1996. He did postdoctoral training at The Cancer Institute of New Jersey and Rutgers University, USA, in Molecular Biology, Pharmacology & Experimental Therapeutics from 2000 to 2002.
Dr. Wu published around 60 papers including 17 SCI papers and edited 2 books for Gynecologic Oncology. He is editorial-board member of Chinese Journal of Gynecology and Obstetrics, China Oncology, and reviewer for Gynecologic Oncology and International Journal of Gynecologic Oncology.
He was awarded grants from Natural Science Foundation of China (NSFC) in 2006 and 2010.
Changlin Mei
Director of the Department of Internal Medicine and Director of the Department of Nephrology of Changzheng Hospital, chief physician, professor and doctoral supervisor
Prof.Changlin Mei is the Director of the Department of Internal Medicine and Director of the Department of Nephrology of Changzheng Hospital, chief physician, professor and doctoral supervisor.
Prof. Mei has long been engaged in the diagnosis and treatment of chronic kidney disease, uremia, rheumatoid arthritis and systemic lupus erythematosus, and has rich clinical experience, especially in the research on the molecular pathogenesis of polycystic kidney disease and the diagnosis and treatment of polycystic kidney disease, and has rich experience in the management of hemodialysis and its complications in uremic patients. In 1993, he went to the United States for training, and after returning to China in 1995, he established two laboratories for immunobiochemistry and pathology of nephropathy under his leadership and conducted many researches. The hemodialysis center established by him has become one of the leading hemodialysis centers in Shanghai and one of the four largest hemodialysis centers in China with the largest scale and most patients treated. The Department of Nephrology under his leadership has developed into an army-wide nephrology technology center and a nephrology research institute. In the past 10 years, he has won one first prize of Shanghai Medical Science and Technology, one second prize of Chinese Medical Science and Technology Award, one third prize of Shanghai Science and Technology Progress, six second and third prizes of Army Science and Technology Progress, and eight major projects of the National Natural Science Foundation of China, such as "863", with a total amount of 3.77 million RMB. In 1993, he was awarded the first prize of the fourth "Silver Snake Award" in Shanghai. He was selected as one of the first batch of "100 outstanding cross-century discipline leaders" training program in Shanghai. In 2001, he was awarded the special government allowance by the State Council, and in 2005, he was awarded the China Physician Award.
Jiang Hua Chen
First Affiliated Hospital of Zhejiang University, School of Medicine
He is interested in CKD、ESRD、Kidney transplantation. He has published more than 450 papers in domestic and international journals, including JAMA Intern Med, JASN, Kidney Int, AJT, CJASN, AJKD, NDT, Intensive Care Med, et al.
Professional Memberships:
Chairman of Chinese Society of Nephrology (CSN)
Chairman of artificial organ branch of Chinese Society of Biomedical Engineering（CSBME）
Vice-chairman of kidney transplantation branch of China Health Care International Exchange Promotion Association
Deputy Director and Secretary-General of the ministry of health of Management Committee of Chinese Scientific Registry of Kidney Transplantation
Director of Zhejiang Province branch of Chinese Society of Biotechnology .
CN
EN
